Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study.

ABSTRACT:

SUBMITTER: Van Voorhees AS 

PROVIDER: S-EPMC8518877 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature